Epidihydrocholesterin

Epidihydrocholesterin

SCHEMBL776234

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OSBP P22059 1/20 0.78
OSBP2 Q969R2 1/20 0.78
CYP2C19 P33261 2/20 0.76
CYP2D6 P10635 1/20 0.76
ST6GAL1 P15907 2/20 0.75
INPP5D Q92835 1/20 0.74
GPBAR1 Q8TDU6 5/20 0.72
CASP7 P55210 3/20 0.72
HIF1A Q16665 3/20 0.72
TP53 P04637 2/20 0.72
MAPK1 P28482 2/20 0.72
HSD17B10 Q99714 2/20 0.72
BLM P54132 2/20 0.72
TDP1 Q9NUW8 2/20 0.72
VDR P11473 2/20 0.72
USP2 O75604 2/20 0.72
LMNA P02545 2/20 0.72
CYP3A4 P08684 2/20 0.72
MDM4 O15151 1/20 0.72
MAPT P10636 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Epicoprosterol SCHEMBL12607072 1.00 OSBP (0.78) OSBPOSBP2CYP2C19CYP2D6ST6GAL1
Epicoprosterol SCHEMBL16867279 1.00 OSBP (0.78) OSBPOSBP2CYP2C19CYP2D6ST6GAL1
Epicoprosterol SCHEMBL12453190 1.00 OSBP (0.78) OSBPOSBP2CYP2C19CYP2D6ST6GAL1
Epicoprosterol SCHEMBL12806627 1.00 OSBP (0.78) OSBPOSBP2CYP2C19CYP2D6ST6GAL1
Epicoprosterol SCHEMBL24632942 1.00 OSBP (0.78) OSBPOSBP2CYP2C19CYP2D6ST6GAL1
Epicoprosterol SCHEMBL11380074 1.00 OSBP (0.78) OSBPOSBP2CYP2C19CYP2D6ST6GAL1
Epicoprosterol SCHEMBL25267973 1.00 OSBP (0.78) OSBPOSBP2CYP2C19CYP2D6ST6GAL1
Epicoprosterol SCHEMBL11391325 1.00 OSBP (0.78) OSBPOSBP2CYP2C19CYP2D6ST6GAL1
Epicoprosterol SCHEMBL21000320 1.00 OSBP (0.78) OSBPOSBP2CYP2C19CYP2D6ST6GAL1
Epicoprosterol SCHEMBL22018677 1.00 OSBP (0.78) OSBPOSBP2CYP2C19CYP2D6ST6GAL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119633036-A Separation and purification method of oxidation-resistant active chia seed polysaccharide 新疆农业大学 2025-03-18 CN claimed
US-20240301138-A1 POLMERIC TRANSFECTION REAGENTS TO DELIVER NUCLEIC ACIDS FOR HOST CELL MODIFICATION RJH BIOSCIENCES INC. (CA) 2024-09-12 US claimed
WO-2022150921-A1 POLYMERIC TRANSFECTION REAGENTS TO DELIVER NUCLEIC ACIDS FOR HOST CELL MODIFICATION RJH BIOSCIENCES INC. (CA) 2022-07-21 WO claimed
US-11130890-B2 Adhesive composition, adhesive sheet, and method for producing same TOYO INK SC HOLDINGS CO., LTD. (JP) 2021-09-28 US claimed
US-8673271-B2 Compositions for mouth containing an anionic surfactant having reduced astringency KAO CORPORATION (JP) 2014-03-18 US claimed
US-20120270177-A1 DENTAL ULTRASONIC DRUG DELIVERY SYSTEM AND DENTAL ULTRASONIC DRUG DELIVERY METHOD FUKUOKA UNIVERSITY (JP) 2012-10-25 US claimed
EP-2514387-A1 ULTRASONIC DRUG DELIVERY SYSTEM FOR DENTAL USE AND ULTRASONIC DRUG DELIVERY METHOD FOR DENTAL USE Japan Health Sciences Foundation (JP) 2012-10-24 EP claimed
US-7863470-B2 Linear polyethylenimine-sterol conjugates for gene delivery UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2011-01-04 US claimed
US-20070154447-A1 Linear polyethylenimine-sterol conjugates for gene delivery FURGESON DARIN Y 2007-07-05 US claimed
US-7183263-B2 Linear polyethylenimine-sterol conjugates for gene delivery UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2007-02-27 US claimed
WO-2003097714-A1 FAT BINDING USING INTER-POLYMER COMPLEX OF GLUCOSAMINE AND POLYACRYLIC ACID RANBAXY LABORATORIES LIMITED (IN) 2003-11-27 WO claimed
EP-1354604-A1 Combinations for cardiovascular indications G.D. Searle LLC. (US) 2003-10-22 EP claimed
WO-2002087556-A9 PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY ATHEROGENICS INC (US) 2003-03-20 WO claimed
WO-2002087556-A2 PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY ATHEROGENICS, INC. (US) 2002-11-07 WO claimed
CN-1342091-A Combinations of cardiovascular indications SEARLE & CO (US) 2002-03-27 CN claimed
EP-1140187-A1 COMBINATIONS FOR CARDIOVASCULAR INDICATIONS G.D. Searle LLC. (US) 2001-10-10 EP claimed
WO-2000038725-A1 COMBINATIONS FOR CARDIOVASCULAR INDICATIONS G.D. SEARLE LLC (US) 2000-07-06 WO claimed
EP-0251905-B1 Esters of alginic acid FIDIA SPA (IT) 1994-11-02 EP claimed
CN-87104499-A Novel alginic acid esters 1988-04-06 CN claimed
US-3974188-A PHOSPHATE THE LION DENTIFRICE CO., LTD. (JA) 1976-08-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070154447-A1 Linear polyethylenimine-sterol conjugates for gene delivery LDLR, CETP, CYP11A1 OSBP 227/4885OSBP2 103/4885CYP2C19 4142/4885
US-20240301138-A1 POLMERIC TRANSFECTION REAGENTS TO DELIVER NUCLEIC ACIDS FOR HOST CELL MODIFICATION POLRMT, POLM, PLTP OSBP 1076/4885OSBP2 1216/4885CYP2C19 4822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.